Trial abstract · §3
GHRP2-JP-DIAGNOSTIC — results
Primary endpoint, absolute and relative effect where derivable, and harms as reported.
§3Results
§3.1Primary endpoint
Table 3. Primary endpoint as reported.
| Endpoint | Result as reported | Certainty |
|---|---|---|
| Diagnostic accuracy of a growth-hormone-releasing peptide 2 stimulation test for adult growth-hormone deficiency | Approved in Japan as a diagnostic stimulation agent. The Institute records that a diagnostic authorisation is not a therapeutic authorisation | Moderate |
| Reproduced from the published report. Where the report states a confidence interval the Institute reproduces it; where it does not, none is constructed. | ||
§3.2Endpoint hierarchy
§3.3Harms as reported
Table 5. Adverse events for GHRP-2 from the safety tables the Institute holds for this compound. Where a row names a different trial as its source, the figure is from that trial and not from this one.
| Event | Active, % | Comparator, % | Source trial |
|---|---|---|---|
| Flushing | — | — | Reported in diagnostic use |
| Transient hunger | — | — | Reported |
| Cortisol elevation | — | — | Present, smaller than with hexarelin |
| Prolactin elevation | — | — | Present |
| Dysgeusia | — | — | Reported |
| Headache | — | — | Reported |
Compound Evidence Institute · CEI-TR-0106/3 · https://compoundevidence.com/trials/ghrp2-jp-diagnostic/results/ · retrieved 30 July 2026